Hormone Therapy Can Help Some With Prostate Cancer

But often not needed for early-stage patients, long-running study shows

By Ed Edelson
HealthDay Reporter

Related Encyclopedia • Adenocarcinoma of the Lung and Brain Metastases • AIDS and HIV Infection • Ankylosing Spondylitis • Baldness More... Related Healthscout Videos Optimistic Healing Early Babies: How Soon is Too Soon? Cancer Treatment for Any Size Fever Kills Cancer More... Related Animations • Breast Self-Exam Video • Colon Cancer • Erectile Dysfunction • Menopause More... Related Drug Information • Cialis • Diflucan • Epogen • Flomax More... Related News Articles • Married With Children Paves Way to Happiness • Focused Radiation May Help Some With Lung Cancer • Health Tip: Getting Ready for Birth • Shorter, More Intense Radiation OK for Some Breast Cancers More...

MONDAY, Nov. 2 (HealthDay News) -- A brief course of hormone-blocking therapy can provide small benefits to a specific group of men who get radiation therapy for prostate cancer, a long-running study shows.

Ten-year survival was 62 percent in men with cancers graded as intermediate risk who got treatment that blocked their male hormone activity in addition to radiation therapy, compared to 57 percent of those who got radiation therapy alone, said Dr. Christopher U. Jones, a radiation oncologist at Radiological Associates of Sacramento, a member of the group who reported the results Monday at the American Society for Radiation Oncology annual meeting, in Chicago.

Text Continues Below

---

When biopsies were taken from men in the group, no traces of cancer were found in 78 percent of those having combined hormone-radiation therapy, compared to 60 percent of those who got radiation therapy alone.

The benefit is statistically significant but not huge, because "we weren't expecting large differences" in such cases, Jones said. And while study results already are incorporated in medical practice, it is not the final word on the issue, since the field is still evolving, he said.

"The standard of care in radiation therapy has changed since the study began in 1994," Jones said. "We can now localize treatment more so we give higher doses of radiation, 50 percent higher."

Even the definition of "intermediate risk" has changed over the years, he said. It is based on such factors as levels of prostate-specific antigen, a hormone produced by the gland, and Gleason score, a measure of the prostate's orderly structure.

"Since the study opened, we have more data and are better able to determine who is truly at low risk," Jones said. "Of the 2,000 we enrolled, we now know that 685 were truly low-risk, 1,068 were at intermediate risk and 226 were high-risk."

Page:  1 | 2 | Next >>